Sera Prognostics (SERA) Corporate presentation summary

Market need and healthcare impact

• Preterm birth rates in the US have risen from 9.4% to 10.4% between 2013 and 2024, with NICU admissions increasing from 8.7% to 9.8% between 2016 and 2023.

• Preterm births account for 61% of neonatal costs for in-hospital deliveries, with extremely premature births costing up to $344,355 per delivery and 7-year healthcare costs up to 7x higher than full-term births.

• Traditional screening methods fail to identify 81% of women who will experience preterm birth, and only 20% of pregnant mothers receive information on preterm labor risk at their first prenatal appointment.

Product and scientific innovation

• The PreTRM test is a proteomics-based, blood biomarker test that predicts spontaneous preterm birth risk early in pregnancy, using proteins such as IGFBP4 and SHBG.

• The test integrates seamlessly into prenatal care workflows, with results delivered in about five days from a CLIA-certified, CAP-accredited lab.

• PreTRM is the only clinically validated test for early prediction of premature birth, supported by 8 independent clinical studies and a biobank of 20,000 diverse samples.

Clinical evidence and outcomes

• The PRIME randomized controlled trial (n=5,018) showed 20% fewer NICU admissions, 56% fewer births before 32 weeks, and 32% fewer before 35 weeks with PreTRM-guided care.

• Each day of gestational age gained among the earliest 10% of births was prolonged by 4.5 days on average, reducing neonatal morbidity by 20%.

• Targeted interventions for higher-risk pregnancies included daily low-dose aspirin, vaginal progesterone, and care management.